SWOG clinical trial number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

44% Accrual
Accrual
44%
Open
Phase
44% Accrual
Accrual
44%
Abbreviated Title
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Activated
10/14/2021

Research committees

Gastrointestinal Cancer

Treatment

Temozolomide Capecitabine

Patient Study Materials

Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary

Other Study Materials

Reports & Approvals

Trial Locations

Other Clinical Trials

S2303
SWOG Clinical Trial Number

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
CTSU/A022101
SWOG Clinical Trial Number

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)

Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
S2107
SWOG Clinical Trial Number

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
100% Accrual
Accrual
100%
Open
Phase